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GENOMICS OF ASTHMA
Abstract

Asthma is one of the most common heritable diseases globally, with highly variable clinical
expression and response to treatment that is attributed to underlying genetic differences.
Hundreds of loci on multiple chromosomes are associated with asthma. Genetic testing is not
currently recommended for management, however, recognition of common asthma phenotypes,
which are the result of genetic and environmental interactions, can help to guide treatment
decisions. Asthma phenotypes are divided into two major categories of atopic and non-atopic
disease, with further subdivisions within in each category that are associated with patterns in
clinical presentation and responsiveness to treatment. In general, earlier onset, and allergic
disease will respond well to traditional therapy with inhaled corticosteroids and leukotrienes, as
these medications target corresponding inflammatory pathways for allergic disease. However,
patients with late onset, symptom predominant (lacking inflammation) and obese asthma may be
resistant to standard therapy and may require treatment modification. These patients are at risk
for overuse of inhaled corticosteroids with poor response, and may benefit more by use of long
acting beta agonists, long acting muscarinic agonists, weight reduction, and exercise. Research
into genetic testing for responsiveness to common asthma medications is early stage, but shows
evidence of clinically utility and cost effectiveness.
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Asthma is one of the most common chronic health conditions world-wide, affecting
approximately 8.3% of U.S adults and children 1. Like many common conditions, it tends to run
in families, and individuals with a family history of asthma are four to six-times more likely to
develop disease, with estimates of heritability ranging from 25 to 95% 2. Albeit a common
diagnosis, asthma is now recognized as a highly heterogenous syndrome that can present
differently from person to person. This variation in individual expression is attributed to a
complex interplay of genetic and environmental factors, which are currently only partially
understood 2. Socioeconomic and environmental influences have been long recognized as
significant factors and targeted for intervention. However emerging evidence suggests that
genetic determinants are equally important in the expression and progression of disease, and
research in this area is rapidly gaining focus.
Two primary approaches have been used to identify genes related to development of
asthma: linkage studies and genome wide association studies (GWAS). Linkage studies examine
family members with and without asthma and look for significant patterns in their DNA that
correspond to clinical expression of disease. GWAS, on the other hand, are large-scale
population studies that do not rely on families, in which researchers sequence the entire DNA of
individuals with disease and compare to ethnically-matched individuals without disease to
determine if specific genetic patterns or variants are associated with phenotypes or traits.
Evidence from these studies suggests that asthma has a multifocal, mixed dominance inheritance
pattern (both recessive and autosomal dominant), involving over 100 individual loci on each
chromosome and more than 20 independent chromosomal regions (consisting of millions of
bases) 2,3. However, research is early stage in these areas, and the precise role of individual
genes in expression of asthma remains ambiguous.
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The broad scope for genetic variability helps to explain the marked diversity seen in
clinical practice. When a disease is caused by a consistent or small group of genes (genetic
homogeneity) there is generally greater uniformity in disease expression and therapeutic
response. Because asthma is caused by hundreds of susceptibility genes interacting differently
with each other and the environment, there is potential for substantial heterogeneity in
expression of disease and response to treatment. In fact, it is estimated that genetic factors may
not only account for differences in disease severity, but also for up to 70% of variability in
response to inhaled corticosteroids and 92% of variability in response to short acting beta
agonists 4,5. One such example is Indacaterol, a newer long acting beta agonist currently
approved for treatment of COPD/chronic bronchitis, which is occasionally used in the treatment
of severe asthma. Indacaterol is metabolized by through the UGT1A1 pathway, which is
encoded by a gene complex located on chromosome two 6. Genetic variation at this loci has
been found to result in reduced or absent UGT1A1 activity, with subsequently altered medication
metabolism and marginally higher serum levels at steady state, which may be related to variable
response to this medication 7. Similarly, multiple gene segments have been identified in
relationship to inhaled corticosteroid (ICS) metabolism, and preliminary evidence suggests that
genetic testing for steroid responsiveness may ultimately prove to be both cost and clinically
effective 8. Presently, these tests are not available for mainstream use. However, as the field of
pharmacogenetics continues to develop, it is likely that genetic testing will play a greater role in
clinical management, as it might be used to predict how patients will respond to treatment and
guide future treatment approaches. A list of known medication-genetic interactions with
potential biomarkers is available at the Food and Drug Administration website, and includes long
acting beta agonists (LABA) such as Aformoterol and Formoterol 9.
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At present, genetic testing is not routinely indicated, and treatment is more usefully
guided by asthma phenotype. Phenotypes are the observable characteristics of disease that result
from interactions of genes and environment—i.e. how the patient presents clinically and
responds to therapy. There are some exceptions to this rule, and patients with poor response to
treatment or suspicion of other asthma look-alikes, such as bronchiectasis, ciliary dyskinesia, or
alpha I anti-tripsin disorder, warrant specialty referral and may require further testing 10. In
most circumstances, however, asthma phenotypes can be recognized based on observable
characteristics, such as allergic versus non-allergic disease, responsiveness to inhaled steroids,
age of onset (pediatric versus adult onset), and comorbid obesity 11.
Albeit having similar symptoms (e.g. chest tightness, wheeze, cough), the precipitating
pathology and corresponding approaches to treatment differ by phenotype. While there is no
universal consensus, there appear to be approximately five to seven distinct groups, depending
on source 11. These have been broadly classified into two primary groups: atopic (eosinophilic)
and non-atopic (non-eosinophilic) asthma, also commonly referred to as allergic/non-allergic or
intrinsic/extrinsic asthma 5. In this paper we adhere to "atopic" which infers that the host has a
genetic tendency to produce eosinophils and IgE antibiodies in response to antigens which are
surface markers found on the surface of allergens.
Atopic asthma phenotypes are now recognized to be further subdivided into early onset
(mild, moderate, and severe), late onset (usually severe), and inflammation predominant, the
latter of which presents with fewer symptoms but is associated with mixed eosinophilic and
neutrophilic inflammation and heightened pulmonary remodeling 11. Details on similarities and
differences between phenotypes are presented in Table 1. Non-atopic asthma phenotypes include
late onset obese and symptom predominant asthma, which notable for high levels of symptoms
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but without eosinophilic inflammation. Atopic obese asthma is also clinically distinct from nonatopic obese asthma and can be distinguished by early age of symptom onset with evidence of
allergic inflammation 12. Other sources further categorize phenotypic variations based on
precipitating factors, such as trigger-induced, infection-related, and Asprin-induced respiratory
disease, however these have not been tied to variable treatment responses and may be less
relevant clinically 13.
While knowing specifically which genotype precede each phenotype is not necessary,
ability to identify phenotypes is useful, as responsiveness to treatment does varies between the
phenotypes listed in Table 1 13. Specifically, the majority of control medications used to treat
asthma, such as inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA), and
more recently anti-IgE monoclonal antibody therapy, work by inhibiting allergic inflammatory
pathways, and are thus not as effective for non-atopic asthma.
Allergic inflammation is mediated by the adaptive immune system via IgE antibodies, T
helper cells, and eosinophils. IgE-mediated inflammation has rapid onset following allergen
exposure and may be associated with severe or anaphylactic reactions. In this situation, IgE
antibiodies recognize antigens (markers) on the surface of an allergen, such as pet dander. This
triggers IgE to bind to pro-inflammatory immune cells (mast cells) which trigger release of T
helper type 2 cells (Th2) and histamine, the latter of which is cytotoxic and causes immediate
inflammation. Eosinophils, the other hallmark of allergic asthma, are triggered by the release
interluekins from the Th2 cells 10. This causes further inflammation and increased bronchial
hyperresponsiveness. Thus, atopic asthma is commonly referred to as eosinophilic asthma, and
when severe, Th2 type asthma. Mainstay asthma medications such as ICS and LTRA
specifically target Th2 mediated cytokines, and block the allergic pathways at multiple levels,
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thereby preventing inflammation and symptoms of asthma. Similarly, anti-IgE biotherapy
blocks free serum IgE and prevents initiation of mast cells, histamine and Th2 cells, again
inhibiting the allergic inflammatory pathway.
In contrast to atopic asthma, late onset obese asthma and symptom predominant asthma
phenotypes lack inflammatory pathology via the adaptive immune system and instead trigger
symptoms via T helper type 17 (Th17) pathways, which release an entirely different group of
pro-inflammatory mediators (including neutrophils) that can directly cause bronchial
hyperreactivity with or without inflammation 10. It is critical to note that cytokines produced by
Th17 are not responsive to steroids. Patients with obese and symptom predominant asthma
phenotypes will therefore respond poorly to traditional treatment with ICS and LTRA, and are at
risk for overuse of ICS with minimal benefit 11. Furthermore, in individuals with obese asthma,
mechanical limitations on respiration (i.e. chest wall adipose tissue) can induce further bronchial
hyperresponsiveness and trigger symptoms without underlying inflammation 12. Thus,
individuals with non-allergic asthma may require a different approach to treatment, and may
derived greater benefit from use of long-acting muscarinic agonists (LAMA) or long acting betaagonists (LABA), both of which induce smooth muscle relaxation and alleviate symptoms by
targeting bronchospasm rather than inflammation 12. It is also important to recognize that there
may be overlap between phenotypes, with varying degrees of expression of Th2 and Th17
pathways, which further contributes to heterogeneity of response to treatment and the complexity
of clinical management.
In conclusion, asthma is no longer considered a single disease entity, but is now viewed
as a syndrome comprising multiple phenotypic variations. While genetic testing is not currently
indicated, these variants present clinically with different observable characteristics and responses
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to treatment that are based upon underlying genetic differences and interactions of genes with
environmental factors. Future clinical management of asthma is likely to be increasingly guided
by pharmacogenetics and tailored treatments that target phenotypes specifically. Clinicians
should be aware of current phenotype classifications, monitor for expected responses to
treatment, adjust medication therapy accordingly, and refer to specialist care when expected
outcomes are not achieved.
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Table 1. Asthma phenotypes and clinical features
Phenotype

Pathology

Low

Th2, Th17: Mixed
eosinophilic and
neutrophilic
inflammation

Low symptom levels
High sputum eosinophilia,
Elevated FeNO

Higher dose ICS + LTRA
+/- LABA
+/- Anti-IgE

Low

Th2: Eosinophilic

Atopic
High symptom levels
High sputum eosinophilia
Elevated FeNO

Low to medium dose ICS
or LTRA
+/- LABA

High with
exacerbations

Th2: Eosinophilic

Atopic
High symptom levels
High sputum eosinophilia
Elevated FeNO

Higher dose ICS
+/- LABA
Consider adding LTRA
Anti-IgE if not controlled

Very high

Th2: Eosinophilic

Atopic
High symptom levels
High sputum eosinophilia
Elevated FeNO
Not fully reversible with SABA

Higher dose ICS
+/- LABA
Consider adding LTRA
Anti-IgE if not controlled

Very high

Non-eosinophilic

Normal eosinophils counts
Normal FeNO,
May have COPD overlap

Poor response to ICS
Consider: LABA/LAMA

High

Non-eosinophilic

Normal eosinophils counts
Normal FeNO
Decreased pulmonary function
due to weight
Average BMI = 33

Poor response to ICS
Weight loss
Consider: LABA/LAMA

Inflammation
predominant

Early Onset
Atopic (mild)
Early Onset
Atopic
(severe)

Late Onset
Atopic
(Severe)

Early
Symptom
Predominant

Late Onset
Obese

Clinical features

First line Clinical
Management

Symptoms

Notes: BMI=Body mass index; FeNO=Nitric oxide; ICS=Inhaled corticosteroid; LABA= Long acting beta agonist; LAMA=Long acting muscarinic agonist; LTRA=Leukotriene receptor
antagonist; SABA=Short acting beta agonist; Th2=T helper type 2 cell; Th17=T helper type 17 cell

